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Abstract
Dominant missense mutations in the human serine protease
FAM111A underlie perinatally lethal gracile bone dysplasia and
Kenny–Caffey syndrome, yet how FAM111A mutations lead to
disease is not known. We show that FAM111A proteolytic activity
suppresses DNA replication and transcription by displacing key
effectors of these processes from chromatin, triggering rapid
programmed cell death by Caspase-dependent apoptosis to
potently undermine cell viability. Patient-associated point muta-
tions in FAM111A exacerbate these phenotypes by hyperactivating
its intrinsic protease activity. Moreover, FAM111A forms a complex
with the uncharacterized homologous serine protease FAM111B,
point mutations in which cause a hereditary fibrosing poikilo-
derma syndrome, and we demonstrate that disease-associated
FAM111B mutants display amplified proteolytic activity and
phenocopy the cellular impact of deregulated FAM111A catalytic
activity. Thus, patient-associated FAM111A and FAM111B mutations
may drive multisystem disorders via a common gain-of-function
mechanism that relieves inhibitory constraints on their protease
activities to powerfully undermine cellular fitness.
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Introduction
Proteases regulate virtually all aspects of cell biology. More than
2% of all known human genes encode proteases or protease inhibi-
tors, highlighting the key importance of proteolytic processes in
human physiology (Lopez-Otin & Bond, 2008). Deregulation of
protease functions impacts multiple cellular pathways and is linked
to a range of human diseases such as cancer, arthritis, osteoporosis,
neurodegeneration, and cardiovascular disorders (Lopez-Otin &
Bond, 2008). Proteases have therefore attracted major interest as
potential drug targets and biomarkers (Drag & Salvesen, 2010).
However, despite their central importance for cell and organismal
fitness, many proteases remain largely unstudied.
Work over the past years revealed that dominant missense muta-
tions in the FAM111A and FAM111B genes, which encode proteins
harboring a C-terminal serine protease domain, are the underlying
cause of rare human multisystem syndromes. Point mutations in
FAM111A, a putative host restriction factor that has been linked to
DNA replication via a PCNA-binding PIP box (Fine et al, 2012;
Alabert et al, 2014; Tarnita et al, 2019), give rise to the two pheno-
typically related disorders gracile bone dysplasia and Kenny–Caffey
syndrome, which manifest with a broad spectrum of severe growth
abnormalities including thin and brittle bones, dwarfism, facial
dysmorphism, and splenic hypoplasia (Unger et al, 2013; Isojima
et al, 2014; Nikkel et al, 2014). In the case of gracile bone dysplasia,
this is typically accompanied by perinatal lethality (Unger et al,
2013). FAM111B encodes a homologous but so far uncharacterized
serine protease, mutations in which are causative of a Rothmund–
Thomson-like syndrome characterized by poikiloderma, myopathy,
pulmonary fibrosis, and tendon contractures (Khumalo et al, 2006;
Mercier et al, 2013, 2015). The range of known patient-associated
FAM111A and FAM111B mutations all map to the periphery of their
protease domains, yet the molecular basis of how these mutations
lead to disease and whether they are caused by loss- or gain-of-func-
tion mechanisms is not known. This is compounded by an almost
complete lack of insight into the biological roles of these proteases.
In particular, the properties and cellular functions of FAM111A and
FAM111B enzymatic activities have not been studied. Accordingly,
how FAM111 proteases function in normal physiology and how this
is undermined by pathological point mutations in these proteins
represent significant knowledge gaps.
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In this study, we discovered that elevated FAM111A protease
activity represses essential chromatin-associated processes including
DNA replication and transcription, triggering rapid cell death by
apoptosis. Remarkably, these properties are exacerbated by patient-
associated FAM111A mutants, due to the amplification of their
intrinsic protease activity. Furthermore, we discovered a physical
link between FAM111A and FAM111B and found that disease-asso-
ciated FAM111B mutants phenocopy the cellular impact of elevated
FAM111A proteolytic activity, likewise resulting from a loss of inhi-
bitory constraints on FAM111B catalytic activity. These findings
shed first light on the powerful adverse impact of elevated FAM111
protease activity on essential chromatin-associated processes and
cellular fitness, and suggest that heterozygous point mutations in
human FAM111A and FAM111B lead to multisystem disease via a
common gain-of-function mechanism unleashing their cytotoxic
proteolytic activities.
Results and Discussion
Human FAM111A and FAM111B are active proteases
The FAM111 family proteases FAM111A and FAM111B harbor
C-terminal serine protease domains that have not been mechanisti-
cally and functionally characterized (Fig 1A). Sequence analysis of
the human FAM111A and FAM111B protease domains revealed that
they contain evolutionarily conserved catalytic triads and display
homology to stress-responsive Escherichia coli Deg-type proteases,
suggesting they are catalytically active (Figs 1B, and EV1A and B).
Supporting this, in silico structural modeling analysis suggested that
both the FAM111A and FAM111B active sites adopt conforma-
tions with notable similarity to that of the E. coli DegS protease
(Fig 1C–F). Using purified recombinant full-length human FAM111A
and FAM111B proteins, we validated that both are active proteases
in vitro, as evidenced by the formation of auto-cleavage products
that were dependent on an intact catalytic triad and abolished by
treatment with the serine protease inhibitor AEBSF (Figs 1G and H,
and EV1C–G). Strikingly, we noticed that elevated expression of
wild-type (WT) FAM111A but not a catalytically inactive D439N
mutant in human cells led to a drastic loss of cell viability, whereas
the expression of WT FAM111B had no impact (Figs 1I and 2A; see
also Fig 5J). These data suggest that human FAM111A and
FAM111B harbor intrinsic proteolytic activity, which at least in the
case of FAM111A potently undermines cellular fitness.
FAM111A proteolytic activity inhibits DNA replication via the
RFC complex
The adverse impact of FAM111A proteolytic activity on cell
survival prompted us to further explore its cellular function. To
this end, we generated stable cell lines conditionally expressing
WT GFP-tagged human FAM111A or mutant alleles containing
inactivating substitutions in the protease domain (D439N) or PIP
box (*PIP) (Alabert et al, 2014) at two- to fourfold higher levels
than endogenous FAM111A (Fig 2A; Appendix Fig S1A). The
higher expression level of the inactive D439N mutant relative to
GFP-FAM111A WT likely reflects its lack of cytotoxicity (Fig 1I).
Using these cell lines, we assessed the impact of FAM111A
protease activity on DNA replication status, given the known
interaction of FAM111A with replication forks (Alabert et al,
2014; Wessel et al, 2019). EdU incorporation analysis revealed
that the expression of ectopic FAM111A in U2OS cells rapidly
and potently suppressed DNA replication in a manner that was
fully dependent on its protease activity (Fig 2B–D). Elevated
FAM111A WT expression also reduced DNA synthesis rates in
HCT116 cells (Appendix Fig S1B). Induction of WT but not
catalytically inactive FAM111A triggered a substantial decrease in
the association of PCNA but not the MCM complex with chro-
matin in S phase cells (Fig 2C, E and F). The resulting decline in
PCNA replication foci intensity was accompanied by RPA accu-
mulation at these sites (Appendix Fig S1C and D), indicating that
FAM111A-mediated dissociation of the PCNA module from active
replisomes triggers replication stress. While FAM111A has been
suggested to promote PCNA loading during DNA replication
(Alabert et al, 2014), we observed no detectable impact of
CRISPR/Cas9- or siRNA-mediated depletion of endogenous
FAM111A on PCNA chromatin association, DNA synthesis rates,
and cell proliferation (Appendix Fig S2A–H), suggesting it is
dispensable for DNA replication per se but may have a perturba-
tion-dependent function in regulating this process. Unlike the
FAM111A protease domain, mutation of the PIP box that abro-
gates PCNA binding (Alabert et al, 2014) did not impair the abil-
ity of FAM111A to suppress DNA replication and PCNA loading
(Fig 2A and C–E). This raised the possibility that FAM111A
predominantly exerts its protease-dependent impact on DNA repli-
cation via other replisome components. Supporting this idea, an
unbiased FAM111A interactome analysis revealed the replication
factor C (RFC) complex, the main cellular PCNA loader (Shiomi
& Nishitani, 2017), but not PCNA itself as a major replication
fork-associated cellular FAM111A-binding partner (Fig 2G; Dataset
EV1), in agreement with genetic data indicating a link between
FAM111A and RFC subunits in restricting viral replication (Panda
et al, 2017). Co-immunoprecipitation experiments suggested that
FAM111A associates with the RFC complex through interaction
with the RFC1 subunit independently of the PIP box, involving a
region of the extended regulatory N-terminal portion of human
RFC1 that encompasses its BRCT domain (Shiomi & Nishitani,
2017) (Figs 2H and I, and EV2A and B). In line with this,
endogenous FAM111A and RFC1 colocalized in nucleoli in G1
and G2 phases and formed nuclear foci during S phase
(Fig EV2C–E). Ectopic FAM111A expression diminished RFC1
chromatin association but not total cellular RFC abundance in a
protease-dependent but PIP box-independent manner (Figs 2J and
K, and EV2F), which may account for its suppressive impact on
PCNA loading. These findings show that FAM111A proteolytic
activity strongly inhibits DNA replication, involving the displace-
ment of both RFC and PCNA from chromatin.
FAM111A protease activity suppresses transcription and triggers
Caspase-dependent apoptosis
We next asked how FAM111A proteolytic activity impairs cell
survival. Induction of FAM111A WT or *PIP but not the catalytically
inactive D439N mutant in U2OS cells led to robust formation of
Caspase 3 and PARP1 cleavage products as well as extensive DNA
fragmentation demarcated by accumulation of cells with sub-G1
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DNA content and pan-nuclear c-H2AX positivity, phenotypes that
could be suppressed by the pan-Caspase inhibitor Z-VAD-FMK but
were insensitive to p53 status (Figs 3A–D and EV3A–D). We there-
fore concluded that elevated FAM111A protease activity potently
triggers programmed cell death via Caspase-dependent apoptosis.
Ectopic FAM111A expression also elicited an apoptotic response in
HCT116 cells (Fig EV3E). While FAM111A-mediated apoptosis had
no impact on DNA replication suppression and proceeded with
slower kinetics, it affected cells at all stages of interphase
(Fig EV3F–H), suggesting that the adverse impact of FAM111A
protease activity on cell viability is not solely a consequence of
disrupting DNA synthesis. Indeed, in addition to its effect on DNA
replication, elevated expression of FAM111A suppressed transcrip-
tion with comparable kinetics in a manner that was largely depen-
dent on its proteolytic activity but neither the PIP box nor cell cycle
status (Figs 2B and 3E–G, and EV3I). Consistently, similar to its
impact on RFC1, induction of catalytically active FAM111A led to a
robust decrease in chromatin-bound but not total levels of RPB1,
the catalytic subunit of RNA polymerase II, and FAM111A and RPB1
formed a complex in cells (Figs 3H–J and EV2A). Thus, elevated
FAM111A protease activity antagonizes essential chromatin-asso-
ciated processes including replication and transcription by evicting
key effectors of these processes, the collective action of which may
lead to rapid cell death by Caspase-dependent apoptosis.
Patient-associated mutations hyperactivate FAM111A protease
activity and its adverse impact on cellular fitness
Dominant missense mutations in human FAM111A, which cluster
on the periphery of the protease domain and are predicted by our
structural modeling to be surface-exposed (Figs 1E and 4A), are
causative of the skeletal disorders Kenny–Caffey syndrome and peri-
natally lethal gracile bone dysplasia (Unger et al, 2013; Isojima
et al, 2014; Nikkel et al, 2014; Abraham et al, 2017), yet how these
mutations impair normal physiology is not known. To address this,
we generated a panel of cell lines conditionally expressing different
patient-associated FAM111A alleles or FAM111A WT at a compara-
ble, near-endogenous level (designated WT (low)) (Figs 4B and
EV4A–D). Like the stable GFP-FAM111A WT-expressing cell line
used above (Fig 2A), the WT (low) cells also suppressed DNA repli-
cation albeit with slower kinetics, due to the lower level of ectopic
GFP-FAM111A WT expression (Figs 4C and EV4A–C). Strikingly,
despite their low abundance, the disease mutants strongly exacer-
bated the impact of GFP-FAM111A on the kinetics and magnitude of
DNA replication and transcription inhibition as well as apoptosis
onset (Figs 4B–F and EV4E–I). Consistently, mutant FAM111A
markedly enhanced RFC1 and RPB1 dissociation from chromatin
(Figs 4G and H, and EV4J and K). We observed similar effects in
cells expressing untagged ectopic FAM111A disease mutants, ruling
◀ Figure 1. Human FAM111A and FAM111B are active proteases.A Domain organization of human FAM111A and FAM111B proteins.
B Alignment of the serine protease domains in human FAM111A, human FAM111B, and Escherichia coli DegS. Red boxes denote fully conserved residues; yellow boxes
indicate conservative amino acid substitutions; and purple stars indicate catalytic triad residues.
C Crystal structure of monomeric E. coli DegS protease (PDB ID: 2R3U). Zoomed-in view shows position of catalytic triad residues (yellow).
D Homology-based protease domain model of human FAM111A (residues 371–555; teal). Zoomed-in view shows catalytic triad residues (yellow). Residues mutated in
human disease (red) are indicated.
E Homology-based protease domain model of human FAM111B (residues 471–664; blue). Zoomed-in view shows catalytic triad residues (yellow). Residues mutated in
human disease (red) are indicated.
F Overlay of the DegS, FAM111A, and FAM111B protease domains in (C–E).
G Purified recombinant FLAG-FAM111A proteins were incubated at indicated temperatures for 4 h, and FAM111A auto-proteolytic activity was analyzed by
immunoblotting with FLAG antibody.
H As in (G), using recombinant human FLAG-FAM111B proteins.
I U2OS cell lines conditionally expressing indicated GFP-FAM111A alleles were fixed at the indicated times after treatment with doxycycline (DOX) to induce expression
of the transgenes and stained with crystal violet. Levels of stably expressed GFP-FAM111A proteins are shown in Fig 2A.
Data information: Data are representative of at least three (G–I) independent experiments with similar outcomes.
▸Figure 2. FAM111A proteolytic activity displaces RFC from chromatin and inhibits DNA replication.A Immunoblot analysis of stable U2OS cell lines left untreated or incubated with DOX to induce expression of WT or mutant forms of GFP-FAM111A.
B DNA replication rates in U2OS/GFP-FAM111A cells treated with DOX for the indicated times, pulse-labeled with EdU, and stained with DAPI were analyzed by
quantifying EdU signal intensity in S phase cells using quantitative image-based cytometry (QIBC) (red bars, mean (A.U., arbitrary units); n > 2,000 cells per
condition). See also Appendix Fig S6A.
C Cells treated as in (B) were pre-extracted, fixed, and stained with PCNA or MCM2 antibody, and subsequently analyzed by QIBC (n > 2,000 cells per condition).
D–F Quantification of data in (C) (red bars, mean). Cells in S phase were identified based on EdU positivity. See also Appendix Fig S6B–D.
G Analysis of FAM111A interactors. U2OS/GFP-FAM111A WT cells were treated or not with DOX for 4 h, subjected to GFP immunoprecipitation (IP), and analyzed by
mass spectrometry. Volcano plot shows enrichment of individual proteins (+DOX/DOX ratio) plotted against the P value. Dashed lines indicate the significance
thresholds (FDR < 0.05; s0 = 1).
H U2OS or U2OS/DFAM111A cells were subjected to IP with IgG (control) or RFC1 antibody followed by immunoblotting with indicated antibodies.
I U2OS cells transfected with empty vector (EV) or indicated RFC subunit expression plasmids were subjected to FLAG IP and immunoblotted with indicated
antibodies.
J As in (C), except that cells were stained with RFC1 antibody (n > 2,000 cells per condition).
K Quantification of data in (J) for S phase (EdU-positive) cells (red bars, mean).
Data information: Data are representative of at least three (A–F, H–K) and two (G) independent experiments with similar outcomes.
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out a contribution of epitope tagging to these phenotypes (Fig EV4L
and M). Moreover, complementation experiments showed that sub-
endogenous levels of disease-associated FAM111A alleles were suffi-
cient to trigger apoptosis in cells depleted of endogenous FAM111A
(Fig EV4M). Introducing an inactivating D439N substitution abro-
gated the impact of the patient-associated FAM111A mutants on
DNA replication, transcription, and apoptosis (Figs 4B–H and EV4I–
K), raising the possibility that they aggravate FAM111A-dependent
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Figure 3. FAM111A protease activity suppresses transcription and triggers Caspase-dependent apoptosis.
A Immunoblot analysis of U2OS/GFP-FAM111A WT cells treated with DOX for the indicated times.
B Representative images of U2OS/GFP-FAM111A cell lines that were treated or not with DOX, fixed, and stained with c-H2AX antibody and DAPI.
C Cells in (B) were subjected to QIBC analysis of c-H2AX signal intensity (red bars, mean (A.U., arbitrary units); n > 2,000 cells per condition). See also Appendix
Fig S6E.
D Immunoblot analysis of U2OS/GFP-FAM111A WT cells treated or not with DOX and the pan-Caspase inhibitor Z-VAD-FMK as indicated.
E–G Transcriptional activity in U2OS/GFP-FAM111A cells treated or not with DOX for the indicated times, pulse-labeled with EU, and stained with DAPI were analyzed
by QIBC (red bars, mean; n > 2,000 cells per condition). See also Fig EV3I for the impact of the FAM111A *PIP mutant and Appendix Fig S6H.
H U2OS/GFP-FAM111A cell lines treated or not with DOX were pre-extracted, fixed, and stained with RPB1 antibody, and analyzed by QIBC (n > 2,000 cells per
condition).
I Quantification of data in (H) (red bars, mean). See also Appendix Fig S6I.
J Representative images from the experiment in (H). Scale bars, 10 lm.
Data information: Data (A–J) are representative of at least three independent experiments with similar outcomes.
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phenotypes by amplifying its catalytic activity. Supporting this
notion, FAM111A cleavage fragments that required its intrinsic
protease activity but were insensitive to Caspase inhibition by Z-
VAD-FMK were observed for disease-associated mutants but not the
WT protein (Fig 4I and J). Importantly, using purified recombinant
proteins we observed elevated auto-proteolytic cleavage of a
FAM111A disease mutant in vitro (Figs 4K, and EV1C and D),
providing direct evidence that patient-associated FAM111A muta-
tions amplify its protease activity. In contrast, introducing a disease
mutation had negligible impact on the subcellular localization of
FAM111A and its association with interacting proteins (Figs 4L and
EV4G). While dominant mutations in FAM111A underlie Kenny–
Caffey syndrome, a variant form of this disorder can also be caused
by recessive mutations in the tubulin-specific chaperone TBCE (Par-
vari et al, 2002). Similar to elevated FAM111A protease activity, we
found that loss of TBCE expression led to impaired cell survival,
and FAM111A patient mutants perturbed microtubule organization
in a protease-dependent manner (Appendix Fig S3A–F), reminiscent
of the impact of disease-associated TBCE mutations (Parvari et al,
2002), further implicating deregulated FAM111A protease activity in
Kenny–Caffey syndrome etiology. Taken together, the data suggest
that patient-associated point mutations in human FAM111A exert
their adverse impact on cell and organismal fitness by hyperactivat-
ing its intrinsic protease activity.
Disease-associated FAM111B mutants have amplified proteolytic
activity and phenocopy FAM111A-induced cellular phenotypes
Heterozygous missense mutations in human FAM111B (Fig 5A) are
causative of a Rothmund–Thomson-like syndrome, whose molecu-
lar basis has not been explored (Khumalo et al, 2006; Mercier et al,
2013, 2015). As for FAM111A, all known patient-associated
FAM111B mutations are found near the protease domain boundaries
and are predicted to be surface-exposed based on our in silico
modeling analysis (Figs 1E and 5A), suggesting possible commonali-
ties in the mechanisms underlying their disease-promoting potential.
Interestingly, our FAM111A interactome analysis revealed FAM111B
as a candidate FAM111A-binding protein (Fig 2G; Dataset EV1).
Indeed, an association between FAM111A and FAM111B in cells
could be readily detected by reciprocal co-immunoprecipitation
analysis, and in vitro binding experiments with purified proteins
demonstrated that this interaction is direct (Fig 5B–D). The cellular
function of FAM111B is unknown, but unlike FAM111A it lacks a
recognizable PIP box and shows no detectable enrichment at DNA
◀ Figure 4. Patient-associated mutations hyperactivate FAM111A protease activity to exacerbate its adverse impact on cellular fitness.A Overview of heterozygous FAM111A mutations found in patients with gracile bone dysplasia or Kenny–Caffey syndrome.
B Immunoblot analysis of U2OS cell lines left untreated or incubated with DOX to induce expression of the indicated GFP-FAM111A alleles.
U2OS/GFP-FAM111A WT (low) cells express the transgene at a lower level than U2OS/GFP-FAM111A WT cells used in Figs 1 and 2 (see Fig EV4A).
C U2OS/GFP-FAM111A cell lines treated or not with DOX, pulse-labeled with EdU, and stained with DAPI were analyzed for DAPI and EdU signal intensity using QIBC.
D Quantification of data in (C) for S phase (EdU-positive) cells (red bars, mean (A.U., arbitrary units); n > 2,000 cells per condition). See also Appendix Fig S6J.
E As in (C), except that cells were pulse-labeled with EU.
F Quantification of EU incorporation in cells in (E) (red bars, mean; n > 2,000 cells per condition). See also Appendix Fig S6L.
G U2OS/GFP-FAM111A cell lines that were treated or not with DOX were stained with RFC1 antibody, pre-extracted and fixed, and stained with DAPI. RFC1 and DAPI
signal intensities were analyzed by QIBC.
H As in (G), except that cells were stained with RPB1 antibody.
I Immunoblot analysis of U2OS/GFP-FAM111A cell lines treated or not with DOX in the absence or presence of Z-VAD-FMK.
J As in (I), using U2OS cell lines conditionally expressing ectopic untagged FAM111A alleles.
K Purified recombinant FLAG-FAM111A proteins were incubated at indicated temperatures for 4 h, and FAM111A auto-proteolytic activity was analyzed by
immunoblotting.
L GFP IPs from U2OS cell lines expressing GFP-FAM111A WT or D528G mutant were analyzed by mass spectrometry. Volcano plot shows enrichment of individual
proteins (WT/D528G ratio) plotted against the P value. Dashed lines indicate the significance thresholds (FDR < 0.05; s0 = 1).
Data information: Data are representative of at least three (B–K) and two (L) independent experiments with similar outcomes.
▸Figure 5. Disease-associated FAM111B mutants have amplified proteolytic activity and phenocopy FAM111A-induced cellular responses.A Domain organization of human FAM111B and overview of disease-associated heterozygous missense mutations.
B U2OS/GFP-FAM111A WT cells treated or not with DOX were subjected to GFP IP followed by immunoblotting with indicated antibodies.
C As in (B), using U2OS/GFP-FAM111B WT cells.
D Purified recombinant FLAG-FAM111A and FLAG-FAM111B proteins were incubated separately or mixed, subjected to IP with FAM111A antibody, and immunoblotted
with FLAG antibody.
E Immunoblot analysis of U2OS/GFP-FAM111B cell lines treated or not with DOX in the absence or presence of Z-VAD-FMK.
F Cells in (E) were pulse-labeled with EdU, stained with DAPI, and analyzed for DAPI and EdU signal intensity using QIBC.
G Quantification of data in (F) for S phase (EdU-positive) cells (red bars, mean (A.U., arbitrary units); n > 2,000 cells per condition). See also Appendix Fig S6N.
H As in (F), except that cells were pulse-labeled with EU.
I Quantification of EU incorporation in cells in (H) (red bars, mean; n > 2,000 cells per condition).
J U2OS/GFP-FAM111B cell lines (Fig 5E) were fixed at the indicated times after DOX treatment and stained with crystal violet.
K Cells in (E) were fixed, immunostained with c-H2AX antibody, and subjected to QIBC analysis of c-H2AX signal intensity (red bars, mean; n > 2,000 cells per
condition). See also Appendix Fig S6O.
L Immunoblot analysis of purified recombinant FLAG-FAM111B proteins and their auto-cleavage products.
Data information: Data (B–L) are representative of at least three independent experiments with similar outcomes.
8 of 14 EMBO reports 21: e50662 | 2020 ª 2020 The Author










FLAG-FAM111A+           -         +























Z-VAD-FMK-     -     -     -     -     -     +    +    +    +    +    +




































































































































































































Z-VAD-FMK-   -   -   -   -   -   +   +   +   +   +   +   



















































































2N 4N 2N 4N 2N 4N 2N 4N 2N 4N 2N 4N
WTWT (-DOX) Q430PS628N









































































ª 2020 The Author EMBO reports 21: e50662 | 2020 9 of 14
Saskia Hoffmann et al EMBO reports
replication sites (Fig EV5A; Wessel et al, 2019). Similar to
FAM111A, we found that FAM111B was dispensable for normal
DNA replication, PCNA chromatin loading, and cell proliferation
(Appendix Fig S2A–H). Remarkably, however, using cell lines
expressing GFP-tagged disease-associated FAM111B alleles at
endogenous levels (Fig 5E and Appendix Fig S4A) we found that
despite FAM111A and FAM111B mutations are associated with dif-
ferent syndromes, FAM111B patient mutants phenocopied the abil-
ity of elevated FAM111A protease activity to potently trigger
replication and transcription shutdown, disruption of microtubule
network integrity, and cell death via Caspase-dependent apoptosis
(Fig 5E–K; Appendix Fig S4B–D). This suggests that FAM111A
and FAM111B have at least partially overlapping cellular func-
tions, consistent with these proteases forming a joint complex. In
line with this, FAM111B also interacted with RFC subunits and
RPB1, and the expression of a FAM111B disease mutant
promoted dissociation of RFC1, PCNA, and RPB1 from chromatin
(Fig EV5B–H). Unlike FAM111A, however, these phenotypes were
only induced by the expression of patient-associated FAM111B
alleles but not the WT protein in our cell lines (Figs 5E–K, and
EV5B and E–H; Appendix Fig S4A–D). Consistently, FAM111B
disease mutants showed prominent Caspase-independent forma-
tion of faster-migrating cleavage fragments that were not
observed for WT FAM111B (Fig 5E; Appendix Fig S4C). Impor-
tantly, an inactivating D544N substitution in the catalytic
protease domain of FAM111B disease mutants abolished their
impact on DNA synthesis, transcription, microtubule organization,
and apoptosis induction, and prevented the appearance of
FAM111B proteolytic cleavage products (Figs 5E–K and EV5E–H;
Appendix Fig S4D). Moreover, a disease-associated FAM111B
S628N mutant displayed markedly elevated auto-proteolytic activ-
ity in vitro (Fig 5L, and EV1E). Thus, similar to FAM111A,
patient mutations in FAM111B undermine cellular fitness by elim-
inating inhibitory constraints on its intrinsic protease activity,
imposing a block to DNA and RNA synthesis, and promoting
apoptotic cell death. However, despite FAM111A and FAM111B
form a complex, their adverse impact on DNA-associated
processes was not interdependent, as elevated FAM111A protease
activity triggered these phenotypes in FAM111B-depleted cells
and vice versa (Appendix Fig S5A–F).
Our findings suggest a common gain-of-function mechanism
for how dominant mutations in FAM111A and FAM111B lead to
multisystem disorders, driven by illegitimate amplification of their
intrinsic proteolytic activities, which are detrimental to cellular
fitness. Accordingly, identifying the targets of FAM111 protease
activity will be an important task for the future. Although both
RFC1 and RPB1 emerge as attractive candidate FAM111
substrates based on our findings, we have so far been unable to
conclusively establish such relationships. While the biological
functions of FAM111 proteases are not well-understood, our
finding that FAM111 proteolytic activity is dispensable for normal
cell growth but powerfully suppresses DNA replication, transcrip-
tion, and cell viability once elevated is well-aligned with the
putative role of FAM111A as a host restriction factor suppressing
simian virus 40 (SV40) and poxvirus gene expression and DNA
replication (Fine et al, 2012; Panda et al, 2017; Tarnita et al,
2019). When properly controlled, these features could provide an
important contribution toward a general line of defense against
invading viruses and their propagation. Given the strikingly simi-
lar cellular consequences of amplified FAM111A and FAM111B
proteolytic activity, their homologous protease domains, and
direct interaction, it seems likely that FAM111B may also act as
a host restriction factor via a FAM111A-like mechanism of
action.
In keeping with the notion that endogenous levels of patient-
associated FAM111A and FAM111B mutants are sufficient to power-
fully antagonize cellular fitness, the markedly different tissue
expression profiles of FAM111A and FAM111B mRNAs
(Appendix Fig S5G) offer a plausible rationale for why mutations in
these proteases have distinct clinical manifestations despite their
comparable cellular impacts. It is also possible that the cellular func-
tions and substrates of FAM111A and FAM111B do not fully over-
lap. Our collective results suggest a potential of specific inhibitors of
FAM111A or FAM111B catalytic activity as a rational treatment
strategy for patients with fibrosing poikiloderma, gracile bone
dysplasia, or Kenny–Caffey syndrome caused by mutations in these
proteases. Moreover, they provide a foundation for further dissec-
tion of the clinical heterogeneity and precise molecular underpin-
nings of human syndromes caused by mutations in FAM111A and
FAM111B, which may help to shed more light on the physiological
functions of these proteases.
Materials and Methods
Plasmids and siRNAs
Full-length human FAM111A and FAM111B cDNAs were inserted
into the destination vectors pcDNA4/TO/EGFP or pcDNA4/TO
using Gateway LR Clonase (Invitrogen) to allow for doxycycline-
inducible expression of the transgenes. Constructs encoding FLAG-
tagged RFC1 were generated by inserting full-length human RFC1
cDNA into pcDNA3.1+/FLAG and pFLAG-CMV2 vectors (containing
C- and N-terminal FLAG tags, respectively). For expression in yeast,
full-length human FAM111A and FAM111B cDNAs were cloned into
the pYES-FLAG-SNAP-TopII vector. RFC1 deletion fragments were
amplified by PCR and inserted into pcDNA3.1+/FLAG vector. Full-
length human RFC2, RFC3, RFC4, and RFC5 cDNAs were inserted
into the destination vector pcDNA4/TO/HA-FLAG. Point mutations
in FAM111A and FAM111B were introduced using the QuikChange
Site-Directed Mutagenesis Kit (Agilent Technologies) according to
the manufacturer’s protocol. The FAM111A *PIP mutant (Alabert
et al, 2014) was generated by introducing Y24A and F25A substitu-
tions into full-length FAM111A. Plasmids for generation of cell lines
with targeted knockout of FAM111A and/or FAM111B (DFAM111A,
DFAM111B, and DFAM111A+DFAM111B) using CRISPR/Cas9 were
constructed as described (Cong et al, 2013), using the pX459 plas-
mid (Addgene #62988) for Cas9 expression and sgRNA delivery.
Briefly, sgRNA sequences were ordered as complementary primers,
mixed in a 1:1 ratio, and annealed. Subsequently, pX459 was
digested with BbsI and the sgRNA introduced using a normal liga-
tion reaction according to the manufacturer’s instructions (New
England Biolabs). The following sequences were used: FAM111A
sgRNA #2 (forward): 50-CACCGAAGAGCCACAACTAATACCC-30;
FAM111A sgRNA #2 (reverse): 50-AAACGGGTATTAGTTGTGGCT
CTTC-30; FAM111B sgRNA #2 (forward): 50-CACCGTAAAC
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TCACAAGTTAGACGG-30; and FAM111B sgRNA #2 (reverse): 50-
AAACCCGTCTAACTTGTGAGTTTAC-30.
Plasmid DNA and siRNA transfections were performed using
FuGENE 6 Transfection Reagent (Promega) and Lipofectamine
RNAiMAX (Invitrogen), respectively, according to the manufactur-
ers’ protocols. All siRNAs were used at a final concentration of
50 nM. The following siRNA oligonucleotides were used: non-
targeting control (CTRL): 50-GGGAUACCUAGACGUUCUA-30;
FAM111A (#3): 50-GGAGAAUGAUGAUUGGAAA-30; FAM111A (#5):
50-GGGAAGAAUAACAAGAUUA-30; FAM111B (#1): 50-CCUGUU
GAUCAUUGUCUAU-30; p53 (#1): 50-CUACUUCCUGAAAACAACG-30;
p53 (#2): 50-GAAAUUUGCGUGUGGAGUA-30; p53 (#3): 50-GACUC-
CAGUGGUAAUCUAC-30; RFC1: 50-GGUAUGAGCAGUAGGCUUA-30;
TBCE (#1): 50-CAGACUUUCUUACUGCAAU-30; and TBCE (#2):
50-CCUUGAGUCUAACAACAUU-30.
Cell culture
Human U2OS and HCT116 cells were obtained from ATCC. All cell
lines used in this study were cultured in DMEM containing 10% FBS
and were regularly tested negative for mycoplasma infection. To
generate U2OS or HCT116 cell lines inducibly expressing GFP-
tagged or untagged FAM111A as well as GFP-FAM111B WT and
mutant alleles, cells were co-transfected with pcDNA4/TO/GFP or
pcDNA4/TO expression constructs and pcDNA6/TR (Invitrogen).
Positive clones were selected by incubation in medium containing
5 lg/ml blasticidin S (Invitrogen) and 400 lg/ml Zeocin (Invitro-
gen) for 14 days. To generate cell lines with targeted knockout of
FAM111A and/or FAM111B (DFAM111A, DFAM111B, and
DFAM111A + DFAM111B), parental U2OS cells were transfected
with pX459-sgFAM111A#2 (DFAM111A), pX459-sgFAM111B#2
(DFAM111B), or a 1:1 mix of pX459-sgFAM111A#2 and pX459-
sgFAM111B#2 (DFAM111A+DFAM111B) and selected briefly with
puromycin during clonal selection. Clones were screened for
FAM111A and FAM111B expression by immunoblotting. Unless
otherwise indicated, the following drug concentrations were used:
nocodazole (10 lM, Sigma-Aldrich), Z-VAD-FMK (50 lM,
ab120487, Abcam), doxycycline (1 lg/ml, Sigma-Aldrich), and
AEBSF (5 mM, Sigma-Aldrich).
Immunochemical methods
For immunoblotting and immunoprecipitation, which were
performed as previously described (Poulsen et al, 2012), cells were
lysed in EBC buffer (50 mM Tris, pH 7.5; 150 mM NaCl; 1 mM
EDTA; 0.5% NP40; 1 mM DTT) supplemented with phosphatase
inhibitors and protease inhibitor cocktail (Roche). Lysates were then
incubated for 10 min on ice and sonicated. For immunoprecipita-
tions, cleared lysates were incubated with FLAG agarose (Sigma-
Aldrich), GFP-Trap Agarose (Chromotek), or anti-goat RFC1 anti-
body (2 lg/sample) coupled to Protein G agarose beads (Thermo
Fisher Scientific) for 2 h on an end-over-end rotator at 4°C, washed
in EBC buffer, and treated with Benzonase to minimize chromatin-
mediated interactions. Proteins were resolved by SDS–PAGE and
analyzed by immunoblotting. For in vitro binding assays, recombi-
nant proteins were diluted in EBC buffer and incubated with
FAM111A antibody (2 lg/sample) coupled to Protein A Agarose
beads (Thermo Fisher Scientific) at 4°C for 2 h on a rotary wheel,
followed by washes in EBC buffer. For in vitro auto-cleavage assays,
recombinant proteins were incubated in EBC buffer.
Immunofluorescence and high-content imaging analysis
Where indicated, cells were pre-extracted in PBS containing 0.2%
Triton X-100 for 2 min on ice, before fixation with 4% formalde-
hyde for 15 min. If cells were not pre-extracted, they were subjected
to a permeabilization step with PBS containing 0.2% Triton X-100
for 5 min and incubated with primary antibodies diluted in 1%
BSA-PBS for 1 h at room temperature. Following staining with
secondary antibodies (Alexa Fluor; Life Technologies) and 40,6-
diamidino-2-phenylindole dihydrochloride (DAPI, 0.5 lg/ml, DNA
staining) diluted in 1% BSA-PBS for 1 h at room temperature, cells
were mounted onto glass slides using ProLong Gold Antifade
(Invitrogen).
For EdU stainings, cells were treated with EdU (10 lM) for
30 min before fixation and then stained using the Click-iT Plus EdU
Alexa Fluor 647 Imaging Kit (Invitrogen) according to the manufac-
turer’s instructions before incubation with primary antibodies. For
EU stainings, cells were treated with EU (1 mM) for 60 min before
fixation and then stained using the Click-iT RNA Alexa Fluor 594
Imaging Kit (Invitrogen) according to the manufacturer’s
instructions.
Images were acquired with a Leica AF6000 wide-field microscope
(Leica Microsystems) equipped with HC Plan-Apochromat 63×/1.4
oil immersion objective, using standard settings. Image acquisition
and analysis were carried out with Leica Application Suite X soft-
ware (version 3.3.3.16958; Leica Microsystems). Raw images were
exported as TIFF files, and if adjustments in image contrast and
brightness were applied, identical settings were used on all images
of a given experiment. Quantitative image-based cytometry (QIBC)
was performed as described (Toledo et al, 2013). Briefly, cells were
fixed, permeabilized, and stained as described above. Images were
acquired with a scanR inverted high-content screening microscope
(Olympus) equipped with wide-field optics, UPLSAPO dry objectives
(×20, 0.75-NA), fast excitation and emission filter-wheel devices for
DAPI, FITC (fluorescein isothiocyanate), Cy3 and Cy5 wavelengths,
an MT20 illumination system, and a digital monochrome Hama-
matsu ORCA-R2 CCD camera. Automated and unbiased image anal-
ysis was carried out with the ScanR analysis software (version
2.7.1). Data were exported and processed using Spotfire software
(version 10.5.0; Tibco).
Antibodies
Antibodies used for immunoblotting included acetylated a-tubulin
(acetyl K40, ab24610, Abcam (1:5,000 dilution)), actin (MAB1501,
Millipore (1:20,000)), Cleaved Caspase-3 (Asp175, 9661, Cell Signal-
ing (1:1,000)), CTCF (A300-543A, Bethyl (1:500)), FAM111A
(ab184572, Abcam (1:1,000)), FAM111B (HPA038637, Sigma
(1:2,000)), FLAG (A00187, GenScript (1:1,000)), GFP (11814460001,
Roche (1:500)) or sc-8334, Santa Cruz (1:1,000)), GTFC1 (A301-
292A, Bethyl (1:1,000)), histone H2AX (2595, Cell Signaling
(1:1,000)), IFI-16 (sc-8023, Santa Cruz (1:500)), MCM2 (610701,
Clone 46/BM28, BD Transduction Lab (1:1,000)), P53 (sc-126, Santa
Cruz (1:1,000)), PARP-1 (sc8007, Santa Cruz (1:500)), PCNA (sc-56,
Santa Cruz (1:1,000)), RFC1 (ab3566, Abcam (1:1,000)), RFC3
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(ab154899, Abcam (1:1,000)), RFC5 (A300-146A, Bethyl (1:1,000)),
TBCE (A305-485A, Bethyl (1:1,000)), tubulin alpha (T9026, Sigma-
Aldrich (1:5,000)), and vinculin (V9131, Sigma (1:10,000)). Anti-
bodies used for immunoprecipitation (IP) included FAM111A
(ab184572, Abcam, 2 lg/IP) and RFC1 (ab3566, Abcam, 2 lg/IP).
Antibodies used for immunofluorescence included cH2AX (05-636
(Clone JBW301), Millipore (1:500)), FAM111A (ab184572, Abcam
(1:300)), MCM2 (610701, Clone 46/BM28, BD Transduction Lab
(1:500)), PCNA (#2037, Triolab Immunoconcepts (1:500)), RFC1
(sc-271656, Santa Cruz (1:300) or ab3566, Abcam (1:1,000)), RPA2
(NA19L (Clone Ab-3), Roche (1:1,000)), and a-tubulin (T9026,
Sigma-Aldrich (1:5,000)).
DNA fiber assays
Exponentially growing U2OS cells (1 × 106) were labeled with
consecutive pulses of CldU (25 lM) and IdU (250 lM) for 25 min.
Cells were then trypsinized and resuspended in PBS. Cell suspen-
sion (2 ll) was spotted onto Superfrost glass slides and lysed in
buffer containing 200 mM Tris–HCl, pH 7.4; 50 mM EDTA; and
0.5% SDS for 2 min. Slides were tilted at an angle to allow the DNA
to run slowly down the slide and air-dried before fixation in 3:1
methanol:acetic acid. DNA fiber spreads were denatured with 2.5 M
HCl for 90 min before blocking in 2% BSA-PBS with 0.1% Tween
for 30 min. Slides were then incubated with rat anti-BrdU (Abcam,
ab6326; 1:100 dilution) for 1 h to detect CldU. Slides were washed
in PBS-Tween and PBS before antibody cross-linking in 4%
formaldehyde for 10 min. Slides were then incubated with Alexa
Fluor 594 goat anti-rat antibody (Thermo Fisher; 1:100) for 1 h.
Following similar washes, slides were incubated with mouse anti-
BrdU (BD Bioscience, #347580; 1:500) overnight at 4°C to detect
IdU. Slides were washed and incubated with Alexa Fluor 488 goat
anti-mouse antibody (Thermo Fisher; 1:100) for 1 h. After washing,
the slides were air-dried and mounted with 50 ll VECTASHIELD
mounting medium (Vector Laboratories). Track lengths were
measured using ImageJ software.
Proliferation and cell survival assays
Cell lines were seeded in 96-well plates in triplicates, and cell prolif-
eration was determined for 4 days by incubation with 10 lg/ml of
resazurin (Sigma) for 2 h at 37°C. Fluorescence was measured at
590 nm using a plate reader (FLUOstar Omega, BMG Labtech).
The obtained values were normalized to the values of the first day.
For survival assays, cells were seeded in 6-cm dishes and treated
with doxycycline to induce the expression of ectopic FAM111A or
FAM111B alleles for the indicated times. After 72 h, plates were
washed once in PBS, left to dry, and stained with cell staining solu-
tion (0.5% w/v crystal violet, 25% v/v methanol). Finally, plates
were washed three times in deionized water. Images were acquired
using the GelCountTM (Oxford Optronix) colony counter.
Affinity purification and mass spectrometry (AP-MS)
Partial on-bead digestion was used for peptide elution from GFP-
Trap Agarose (Chromotek). Briefly, 100 ll of elution buffer (2 M
urea; 2 mM DTT; 20 lg/ml trypsin; and 50 mM Tris, pH 7.5) was
added and incubated at 37°C for 30 min. Samples were alkylated
with 25 mM CAA and digested overnight at room temperature
before addition of 1% trifluoroacetic acid (TFA) to stop digestion.
Peptides were desalted and purified with styrene–divinylbenzene
reversed-phase sulfonate (SDB-RPS) StageTips. Briefly, two layers of
SDB-RPS were prepared with 100 ll wash buffer (0.2% TFA in
H2O). Peptides were loaded on top and centrifuged for 5 min at
500 g, and washed with 150 ll wash buffer. Finally, peptides were
eluted with 50 ll elution buffer (80% ACN and 1% ammonia) and
vacuum-dried. Dried peptides were dissolved in 2% acetonitrile
(ACN) and 0.1% TFA in water and stored at 20°C.
Liquid chromatography–mass spectrometry (LC-MS) analysis
Nanoflow LC-MS analysis of tryptic peptides was performed using a
quadrupole Orbitrap mass spectrometer [Q Exactive HF-X, Thermo
Fisher Scientific (Kelstrup et al, 2018)] connected to an EASY-nLC
1200 ultra-high-pressure system (Thermo Fisher Scientific). Approx-
imately 0.5 lg of peptides was loaded on a 50-cm HPLC column
(75 lm inner diameter, New Objective; in-house packed using
ReproSil-Pur C18-AQ 1.9 lm silica beads; Dr Maisch GmbH,
Germany). Peptides were separated using a linear gradient from 2 to
20% B in 55 min and stepped up to 40% in 40 min followed by a
5 min wash at 98% B at 350 nl/min, where solvent A was 0.1%
formic acid in water and solvent B was 80% acetonitrile and 0.1%
formic acid in water for a total duration of 100 min. The mass spec-
trometer was operated in “top-15” data-dependent mode, collecting
MS spectra in the Orbitrap mass analyzer (60,000 resolution, 300–
1,650 m/z range) with an automatic gain control (AGC) target of
3 × 106 and a maximum ion injection time of 25 ms. The most
intense ions from the full scan were isolated with an isolation width
of 1.4 m/z. Following higher-energy collisional dissociation (HCD)
with a normalized collision energy (NCE) of 27, MS/MS spectra
were collected in the Orbitrap (15,000 resolution) with an AGC
target of 1 × 105 and a maximum ion injection time of 28 ms.
Precursor dynamic exclusion was enabled with a duration of 30 s.
Bioinformatic analyses
Raw MS files were processed using the MaxQuant software (version
1.6.5.0) (Cox & Mann, 2008). The integrated Andromeda search
engine (Cox et al, 2011) was used for peptide and protein identifi-
cation at an FDR of < 1% and s0 value of 1 (Tusher et al, 2001).
Missing values were imputed based on a normal distribution
(width = 0.15; downshift = 1.8). The human UniProtKB database
(January 2019) was used as forward database and the automatically
generated reverse database for the decoy search. A minimum
number of seven amino acids was used for the peptide identifi-
cation. Proteins that could not be discriminated by unique peptides
were pooled in the same protein group (Cox & Mann, 2008). Label-
free protein quantification was done using the MaxLFQ algorithm
(Cox et al, 2014). Protein ratios were calculated based on median
peptide ratios, and only common peptides were used for pairwise
ratio calculations. The “match-between-runs” feature of MaxQuant
was enabled to transfer peptide identifications across runs based on
high mass accuracy and normalized retention times. All statistical
and bioinformatic analyses were performed using Perseus (Tyanova
et al, 2016) or the R framework (https://www.r-project.org/). The
mass spectrometry proteomic data have been deposited to the
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ProteomeXchange Consortium via the PRIDE (Perez-Riverol et al,
2019) partner repository with the dataset identifier PXD017978.
Purification of recombinant FAM111 proteins
Identical conditions were used for purification of all FLAG-tagged
recombinant FAM111A or FAM111B proteins. Briefly, JEL-1 yeast
strain transformed with FLAG-FAM111A or FLAG-FAM111B expres-
sion plasmid was grown in SC-URA medium containing 2% glucose
for 36 h at 30°C, and subsequently in SC-URA medium containing
2% raffinose for 24 h at 30°C. The culture was then grown in YEP
medium containing 2% raffinose and grown until OD 0.8. FLAG-
FAM111 protein expression was induced by adding galactose (2%)
for 24 h at 20°C. Cells were collected and resuspended in lysis
buffer containing 50 mM Tris, pH 7.5; 500 mM NaCl; 10% glycerol;
1 mM EDTA; and 0.1 mM DTT. Glass beads were added to the
resuspended cells, which were lysed by vortexing and cleared by
centrifugation at 25,000 g at 4°C for 30 min. The cleared lysate was
incubated with FLAG M2 resin (Sigma-Aldrich) and incubated at
4°C for 2 h. After extensive washing, FLAG-FAM111A or FLAG-
FAM111B was eluted in lysis buffer supplemented with FLAG
peptide (0.5 mg/ml). The elute fractions were run on a 4–12%
NuPAGE Bis-Tris protein gel (Invitrogen) and stained with Instant
Blue Coomassie Protein Stain (Expedeon). Fractions were concen-
trated on Microcon-30 kDa Centrifugal Filters (Millipore), snap-
frozen in liquid nitrogen, and stored at 80°C.
Homology modeling of FAM111A and FAM111B protease domains
Domain identification in human FAM111A and FAM111B with
Conserved Domains Database (CDD) (Lu et al, 2020; https://
www.ncbi.nlm.nih.gov/Structure/cdd/wrpsb.cgi) identified resi-
dues 371–555 for FAM111A and residues 471–664 for FAM111B
to contain conserved trypsin-like serine protease domains. Full-
length FAM111A and FAM111B sequences were used as input in
HHpred for the identification of experimental structures of homol-
ogous proteins (https://toolkit.tuebingen.mpg.de/tools/hhpred).
Among obtained hits, the crystal structure of E. coli DegS protease
(2R3U) at 2.6 Å resolution (Hasselblatt et al, 2007) displayed the
highest degree of homology and was used as a template for
generating FAM111A and FAM111B protease domain models
using MODELLER (Zimmermann et al, 2018). The quality of the
models was assessed based on the Ramachandran plot using
Rampage (http://mordred.bioc.cam.ac.uk/~rapper/rampage.php),
which assigned 85.7% of residues to favored regions (2.9%
outliers) for FAM111A and 88.1% of residues to favored regions
(4.5% outliers) for FAM111B. Overall model quality for both
FAM111A (Z-score: 4.05) and FAM111B (Z-score: 3.82) was
assessed using ProSA-web Protein Structure Analysis (https://
prosa.services.came.sbg.ac.at/prosa.php). PyMol (v2.0) was used
for visualization of the structures.
Flow cytometry
Cells were fixed in 70% ethanol, and DNA was stained with
propidium iodide (0.1 mg/ml) containing RNase (20 lg/ml) for
30 min at 37°C. Flow cytometry analysis was performed on a
FACSCalibur (BD Biosciences) using CellQuest Pro software
(version 6.0; Becton Dickinson). The data were analyzed using
FlowJo software (version 10.6).
FAM111 transcript profiling
Tissue RNA-seq data (RNA HPA tissue gene data) were downloaded
from The Human Protein Atlas (Uhlen et al, 2015) (version 19.3)
and Ensembl (version 92.38).
Data availability
Mass spectrometry proteomic RAW data are available at the Proteo-
meXchange Consortium database via the Proteomics Identifications
(PRIDE) partner repository (http://www.ebi.ac.uk/pride), under
the dataset ID PXD017978. All other data supporting the findings
of this study are available within the article and supplementary
information.
Expanded View for this article is available online.
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